Cited by 52Berberine and alkaloids researchSynthesis and Biological ActivityTraditional Chinese Medicine Analysis

A patent review of berberine and its derivatives with various pharmacological activities (2016–2020)

Kong, Yuan, Li, Lin, Zhao, Lin-Guo, Yu, Pan, Li, Dong-Dong·2022·Expert Opinion on Therapeutic Patents

Abstract

INTRODUCTION: Berberine (BBR), as one of the outstanding representatives of isoquinoline alkaloids, has been used as an antibacterial drug for a long time in China since ancient times. Currently, a large number of studies have been reported that berberine has a wide spectrum of pharmacological activities, such as anti-tumor, anti-inflammatory, hypoglycemic, hypolipidemic, anti-obesity, and the like. AREAS COVERED: This review systematically discussed important patents on berberine and berberine derivatives in terms of pharmacological activity between 2016 and 2020. These patents were mainly searched through the European Patent Office database and Web of Science. These berberine patents (~41) cover a wide range of applications, mainly including antitumor, anti-inflammatory, antibacterial, anti-metabolic disorder, and other newly reported pharmacological activities. EXPERT OPINION: Berberine is an important lead compound with great potential for optimization in drug development. However, there is a lack of research related to the biomolecular targets of BBR, which directly restricts the development of berberine in the pharmaceutical field. The problems involved with poor bioavailability and cytotoxicity are also worth considering in the development of berberine-based drugs. Accordingly, the increasing number of patents involving biomolecular targets in BBR's patent applications will be published as its related pharmacological mechanisms are further deciphered.

Integrity signals

Registry

Crossref · 10.1080/13543776.2021.1974001

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

16 of the 80 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kong, Y., Li, L., Zhao, L.-G., Yu, P., & Li, D.-D.
Affiliations
  • Nanjing Forestry University (CN)
  • Anhui University of Science and Technology (CN)
Corresponding author
  • Zhao, Lin-Guo
  • Yu, Pan
  • Li, Dong-Dong
Venue
Expert Opinion on Therapeutic Patents
Published
2021-09-17
Volume
32
Issue
2
Pages
211-223
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W3196603633
Cited by
52
References
80
Citations by year
2026: 6 · 2025: 20 · 2024: 11 · 2023: 10 · 2022: 4 · 2021: 1
FWCI
0.82
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Patents (publishedVersion)
  • PubMed (publishedVersion)
Funders
Project for Young Teachers of Nanjing Forestry University
Topics
  • Health Sciences › Medicine › Pharmacology › Berberine and alkaloids research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Synthesis and Biological Activity
  • Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Analysis
Keywords
berberine, berberine derivatives, isoquinoline alkaloids, patent analysis, anticancer activity, anti-inflammatory activity, antibacterial activity, anti-obesity, hypoglycemic activity, hypolipidemic activity, bioavailability, cytotoxicity, drug development
MeSH terms
Anti-Inflammatory Agents, Berberine, Biological Availability, Humans, Hypoglycemic Agents, Patents as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review